Rialto Wealth Management’s Astria Therapeutics ATXS Stock Holding History

Rialto Wealth Management’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-40	Closed	-$524	–	1732
2025 Q4	$524	Buy	+40	New	+$478	﹤0.01%	1245

Rialto Wealth Management's ATXS Position: Q1 2026 in Review

Rialto Wealth Management sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 40 shares — an estimated $524 sold.

Rialto Wealth Management first reported a position in ATXS in Q4 2025 and held it in 1 quarter. The position peaked at $524 in Q4 2025. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.

Rialto Wealth Management reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
Rialto Wealth Management sold 40 Astria Therapeutics shares in Q1 2026, an estimated $524.
Rialto Wealth Management first reported a position in Astria Therapeutics in Q4 2025 and held it in 1 quarter.
Rialto Wealth Management's Astria Therapeutics position peaked at $524 in Q4 2025.
0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.

Based on Rialto Wealth Management's 13F filing for Q1 2026, filed 14 May 2026.